BriaCell Therapeutics Corp.
BCTX
$3.62
-$0.0292-0.80%
| 10/31/2024 | 07/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 3.16% | -7.65% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -10.67% | -37.51% | |||
| Operating Income | 10.67% | 37.51% | |||
| Income Before Tax | -366.79% | -173.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -366.79% | -173.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -21.68% | 47.23% | |||
| Net Income | -377.86% | -170.77% | |||
| EBIT | 10.67% | 37.51% | |||
| EBITDA | 10.00% | 38.27% | |||
| EPS Basic | -220.77% | -163.22% | |||
| Normalized Basic EPS | -225.42% | -161.60% | |||
| EPS Diluted | -208.12% | -166.48% | |||
| Normalized Diluted EPS | -225.42% | -161.60% | |||
| Average Basic Shares Outstanding | 49.04% | 11.84% | |||
| Average Diluted Shares Outstanding | 49.04% | 11.84% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
